20112012 corporate responsibility update ecatur etureli lilly 136 year unt content abo cum ni company demonstrated 01 message ceo 03 nullectia rest commitment responsible lilly key performance indicator 05 06 ut vellum global qui citizenincluding long 02 blaborectat conducting business ethically transparently 07 history philanthropic contribution 03 cusam greatestoccul contribution society enhancing access medicine 13 04 however discovering developing developing innovative medicine 19 05 innovative medicine running supporting strong workplace practice 30 06 business ethically responsibly lilly around world 38 07 engaging patient 41 08 fostering environmental sustainability 44 09 united nation global compact index 58 report 59 lorem ipsum message ceo 01 02 03 04 05 06 07 08 09 message ceo dear reader also provide opportunity employee share expertise community around core lillys vision aim improve global world connecting heart abroad signature global health 21st century first foremost service initiative one example launched 2011 creating medicine help people live longer program sends 200 lilly ambassador year healthier active life also believe twoweek community development assignment business important lillys asia africa central south america commitment united nation global compact ungc reflects core value integrity excellence lilly rank among world charitable company respect people integral donating 590 million 2011 cr company since founding 136 year ago charity believe opportunity missed know even improve global health proud present update report highlight bring table expertise chronic disease commitment progress around corporate along financial resource responsibility cr increasingly integrating concept shared u responsibility start treat value way operate using business employee employee play indispensable role expertise help address pressing social need open helping u meet cr commitment turn new opportunity u provide solution health strive encourage maintaining supportive challenge world believe approach respectful working environment put special help create enduring value society lilly emphasis flexibility workplace making individual patient better help honored named diversityincs top patientsas well community broader company working family 2012 societiesto thrive 03 lilly 20112012 corporate responsibility update lorem ipsum message ceo 01 02 03 04 05 06 07 08 09 along investing asset expertise example speke united kingdom manufacturing spearhead broad strategic partnership improve facility new process antibiotic production access health care example decreased water usage 143 million liter per yearor 10 percent total usagewhile reducing steam lilly mdrtb partnership offer education usage 7000 metric tonsor 5 percent overall use training improved care people fighting deadly change helped save 560000 2012 multidrugresistant tuberculosis projected waste stream reduction related initiative lilly ncd partnership launched 2011 could push annual saving 2 million also provide 30 million five year fight rising pleased 2011 10 lilly site globally reported burden noncommunicable disease ncds zero landfill status indicating send less developing nation 05 percent generated waste landfill 2011 announced lilly truassist easytouse proud accomplishment yet onestop resource patientassistance recognize must make progress still program lilly long offered help people committed behalf everyone obtain lilly medication need lilly thank interest company 250000 patient received help program cr update welcome feedback 2011a 12 percent increase previous year environmental arena weve set goal limit impact drawing scientific technical business expertise eliminate waste inefficiency wherever possible john c lechleiter phd chairman president chief executive officer november 30 2012 04 lilly 20112012 corporate responsibility update loremlilly ipsum 01 02 03 04 05 06 07 08 09 lilly fact glance november 2012 lilly make medicine help people live longer healthier active life founded 1876 10th largest pharmaceutical company world 136 7400 55 8 around globe forged productive alliance partnership advance capacity develop innovative medicine lower cost world urgent medical need year strong founded employee engaged country clinical country research may 10 1876 research development research conducted development facility lilly long history medical innovation notably treatment infectious disease diabetes depression today portfolio also includes oncology biomedicine emerging market business unit work deliver medicine address unmet need around world additional information 125 242 usa lly corporate history significant medical breakthrough visit section wwwlillycom country billion worldwide headquartered symbol listed product marketed revenue 2011 indianapolis indiana new york stock exchange united state elanco elanco division lilly focus animal wellbeing animal productivity food safety 75 country company introduced first product veterinary use 1953 today offer 13 38000 30 product elanco employ 2700 people country employee worldwide worldwide office 40 country manufacturing plant global headquarters greenfield indiana united state also base u business operation elanco product marketed primarily cattle poultry swine producer elanco companion animal health develops pet medicine assist veterinarian helping companion animal lead longer healthier life 05 lilly 20112012 corporate responsibility update lorem key ipsum performance indicator 01 02 03 04 05 06 07 08 09 key performance indicator goal 2007 2008 2009 2010 2011 1 2013 goal 2007 baseline three workplacerelated metric health safety data prior year financial highlight adjusted slightly due updated data collection worldwide revenue million 186335 203719 218360 230760 242865 2 following world resource institute wri guidance progress toward environmental goal reported adjusted basis research development million 34867 38409 43265 48842 50208 accounting merger acquisition divestiture appropriate ensure comparability unless stated otherwise 3 2013 goal 2007 baseline workplace highlights1 4 2013 goal 2007 baseline goal cover lillys scope 1 scope 2 emission serious injury rate per 100 employee 50 144 118 092 096 109 5 2013 goal 2010 baseline lilly established goal losttime injury rate per 100 employee 50 062 059 038 041 047 meeting prior goalto reduce water intake absolute term 25 percent 2013 compared 2007four year motorvehicle collision rate collision per million mile driven 50 1110 1206 1117 1048 1028 early water intake used evaluating progress toward waterreduction goal total amount water coming facility including water pumped philanthropy highlight body surface water groundwater water provided utility includes water used process product inkind donation million 240 297 335 373 549 utility ancillary operation irrigation term include groundwater pumped solely cash contribution million 75 53 70 57 48 treatment satisfy regulatory action requirement eg remediation activity water used total contribution million 315 350 405 430 597 another purpose value include water extracted well solely purpose lowering groundwater table maintain physical structural integrity environmental highlights2 building foundation water intake value 2010 adjusted previously reported value due metering energy consumption million btu 12900000 11900000 11300000 11200000 10800000 data evaluation one top water use site energy intensity thousand btussquare foot 153 594 562 543 520 495 6 2013 goal 2010 baseline lilly established goal meeting prior goalto reduce waste landfill 40 greenhouse gas emission scope 1 scope 2 metric ton co2e 1810000 1730000 1640000 1600000 1530000 percent absolute term 2013 compared 2007four year early lillys former current wastetolandfill greenhouse gas emission intensity metric ton co2e1000 square foot 15 4 833 822 782 745 700 goal include construction demolition debris biosolids wastewater treatment plant incinerator water intake billion liter 5 5 196 176 132 128 133 ash coal ash reused mine reclamation road base mycelium urea reused fertilizer unlike water intensity million litersmillion revenue 105 0864 0605 0555 0549 energy greenhouse gas emission waterintake goal performance data used calculate progress waste generation metric ton 379000 387000 287000 228000 242000 wastetolandfill goal exclude data waste generation intensity metric tonsmillion revenue 203 190 131 988 107 tippecanoe laboratory facility indiana united state lilly divested 2009 waste landfill metric ton 206 32000 22300 14800 15900 10900 data site significant impact worldwide wastetolandfill total reportable permitlimit exceedance 7 43 27 16 11 8 7 reportable permitlimit exceedance environmental release air water land outside regulatory limit necessarily result harm people environment 06 lilly 20112012 corporate responsibility update conducting business ethically transparently 01 02 03 04 05 06 07 08 09 02 conducting business ethically transparently lilly action grounded core company value integrity excellence respect people business important strive leader corporate responsibility demonstrate value responsible business practice reflect commitment strong governance principle transparency patient customer employee privacy ethical product promotion stakeholder engagement participation public policy process also demonstrates value affect business 07 lilly 20112012 corporate responsibility update conducting business ethically transparently 01 02 03 04 05 06 07 08 09 acting integrity commitment ethic compliance born lillys global anticorruption program component summarizes key principle global company policy commitment integrity policy code overall gecp includes policy procedure provides example employee practice applying business conduct call red book tailored challenge ensuring compliance principle decision action red compliance management system training 125 country market product book designed provide foundational guiding principle program reinforce ethical behavior implemented global anticorruption program help employee navigate increasingly complex every lilly affiliate worldwide internally require global business environment global leader development manufacture training employee anticorruption issue sale pharmaceutical product implemented red book amplified policy standard including bribery continue refine improveprograms procedure accessible employee company designed promote ethical conduct instill culture chief executive officer routinely set tone intranet document govern lillys action compliance train employee ethical top speaking directly employee ethic respect specific area including anticorruption business practice system place detect compliance issue blog audio privacy product promotion safety medical research potential violation law company policy video message global town hall communication security trading record keeping employee meeting international transaction ethical interaction global ethic compliance program gecp take external party interaction government public comprehensive approach compliance includes training communication designed prevent potential code conduct policy standard official payment grant donation meeting procedure healthcare provider gift product sample many issue arising well reporting auditing topic monitoring detect potential compliance failing ethic compliance program include police invested significant resource formal ethic standard procedure communicate key detailed information compliance compliance program include focused effort compliancerelated expectation variety policy practice found 2010 corporate privacy anticorruption appropriate product vehicle including red book document responsibility report promotion among area available 24 language emphasizes company value importance ethical decisionmaking 08 lilly 20112012 corporate responsibility update conducting business ethically transparently 01 02 03 04 05 06 07 08 09 advancing public policy transparency lilly lilly committed helping people live longer new pricing model experience taught u transparency healthier active life fulfill mission pharmaceutical industry business model operation help build trust believe important ensure patient access become increasingly challenged payer policymakers needed medication lilly participates public policy stakeholder believe patient pay pocket often believe debate around world contributes policy transparency regarding business practice price newer medicine high environment manner support patient access time company discover develop new involve financial payment physician innovative medicinesleading improved patient medicine experiencing unprecedented price erosion help build trust public 2004 outcome since 2010 updated position legislated price cut inappropriate reference differential pricing supported research first company announce pricing restriction physician patient contributes policy effort centered patient access would voluntarily disclose choice wealthier country afford innovative innovative medicine medicine increasingly unwilling pay thema public u clinicaltrial resultseven situation exacerbated global financial crisiswhile unfavorable one also first differential pricing developing country cannot afford innovative medicine developedmarket price company report result thirdparty term refers set policy enables differential pricing medicine within country audit database addition publicly new pricing approach needed promote achieves variable price based patient ability access medicine country varying stage report funding provide united pay order balance desire affordable state institution form educational development reward innovative research price lowincome population simultaneously development many barrier grant charitable contribution rewarding medical advance competitive market accessing medicine developing world financial support patient organization price approach facilitates access medicine associated public policy issue lilly engaged support continued research development number leading academic explore topic based europe financial payment benefit patient public private payer u healthcare professional resulting research published journal health pharmaceutical industry effective differential affair outcome effort informs contracted speaker educational pro pricing must supported environment policy engagement global health stakeholder gram provide u advice free reference pricing strategy establishes hope help foster continued dialogue product price point benchmarking price topic resulting research published health company annual political contribution product country prevents affair health affair 30 8 2011 health affair diversion discounted medicine higherpriced market 29 no12 2010 09 lilly 20112012 corporate responsibility update conducting business ethically transparently 01 02 03 04 05 06 07 08 09 managing supply chain 50 lilly manage supply chain help maintain supporting pharmaceutical supply safe uninterrupted supply medicine within chain initiative operation broader pharmaceutical early 2009 lilly adopted pharmaceutical industry industry work support united nation global principle responsible supply chain management compact principle ensure adherence labor law set forth pharmaceutical supply chain initiative protect environment partner supplier api active pharmaceutical ingredient product psci industry group lilly active around world encourage adopt manufactured lillyowned facility participant psci principle designed align global leadership standard set principle united nation global compact 14 represent highlevel expectation set industry lillys supply chain glance supplier area ethic labor health safety lilly maintains relationship thousand supplier environment related management system material service categorize supplier upon adopting principle lilly revised updated three tier help identify type impact supplier code conduct reflect principle supply risk perspective8 view current lilly supplier code conduct number pharmaceutical company visit wwwsupplierportallillycomsupplierspages 2012 approximately half api active pharmaceutical including lilly shared goal providing conductcodeaspx ingredient product manufactured lillyowned supplier service provider common facility including three site united state well participation psci lilly proud health safety environmental labor ethic site ireland puerto rico united kingdom stand alongside 13 pharmaceutical company business management standard finishing operation including labeling packaging share goal providing supplier service provider take place number site throughout world common health safety environment labor ethic business management standard together industry peer working educate supplier ensure partner operate way consistent company value 8 supply risk risk associated lillys dependence third party either service material critical operation business supply risk come many factor including limited supplier financial stability ability produce provide service quality manner impact natural disaster supplier site risk monitored annual basis mitigation plan implemented monitored minimize 10 lilly 20112012 corporate responsibility update conducting business ethically transparently 01 02 03 04 05 06 07 08 09 lilly fully embrace psci vision part lillys ongoing supply chain risk management lilly supplier type application principle better social economic lilly supplier tier b c must complete annual environmental outcome result involved supplier selfassessment questionnaire available tier pharmaceutical supply chain includes improved audit lillys discretion 2011 together supplier provide good service across range condition worker expanded economic development psci company lilly began exploring best way area needed general office functioning cleaner environment local community ensure monitor compliance among supplier includes general office supply travel service member psci lilly committed influencing began conducting supplier audit work ongoing equipment catering routine service positive social environmental change pharma reported depth next report ceutical industry work build supplier tier b capability area supplier diversity supplier provide raw material common commodity used packaging manufacturing learn lillys management environmental lilly also aspires broaden participation small operation includes packaging material waste impact throughout supply chain see fostering diverse business supplier base since 2005 disposal service energy environmental sustainability section beginning page 44 u small business administration recognized lilly outstanding effort promote tier c upholding human right maintain supplier diversity goal achieve greater supplier provide active pharmaceutical ingredient 10 percent external spend small including specialty chemical supplier tier lilly maintains longstanding practice complying diverse supplier 2011 spent 522 million include active ingredient supplier contract manu local minimumage law requirement diverse supplier exceeding goal 430 million facturers research development lab employ child labor forced compulsory diversesupplier spending labor facility globally 2011 lilly began revising global standard procedure include specific language human right 4 95 1 supplier data includes data elanco animal health division tier c 1 tier b 4 tier 95 11 lilly 20112012 corporate responsibility update conducting business ethically transparently 01 02 03 04 05 06 07 08 09 fighting counterfeit medicine european alliance rank among biggest supply chain concern criminal drawn pharmaceutical counterfeiting access safe medicine international pharmaceutical company like lilly prospect high profit low risk offender raising public awareness protecting public counterfeit medicine rarely prosecuted unregulated environment global sale last year estimated high 200 billion9 full anonymity access patient internet danger posed counterfeit counterfeit medicine big business growing hot spot counterfeiter criminal organization dupe medicine available every part world patient unknowingly customer buying counterfeit medicine fake encountering counterfeit look like actual online pharmacy use image trademarked legitimate supply chain medicine appearance package branded pharmaceutical product internet undertake size color pill dangerous imposter may contain inactive useless ingredientsor lilly actively engaged effort combat counterfeiting major project year lillys partner government others protect even toxic substance arsenic every case health safety patient take medicine muchvalued support help bring counterfeit unreliable case cause harm patient including death lilly founding member steering group participant message wider audience alliance safe online pharmacy broad coalition counterfeit medicine pose real growing threat stakeholder interest protecting patient effect real change patient safety worldwide public health pharmaceutical safety ensuring patient access safe legitimate tremendously proud lilly counterfeiting cross geographic boundary affect online pharmacy europe lilly active european patient suffering variety disease medicine alliance access safe medicine patient stand shouldertoshoulder commonly involved counterfeiting include used education danger counterfeit medicine u important work erectile dysfunction oncology cardiovascular disease mental health preventing proper treatment condition jim thomson chair european alliance access safe medicine 9 source world economic forum global risk 2011 sixth edition initiative risk response network january 2011 12 lilly 20112012 corporate responsibility update enhancing access medicine 01 02 03 03 04 05 06 07 08 09 03 enhancing access medicine around world estimated least billion people lack access comprehensive health care including medicine treatment tool lilly committed expanding access medicine health care work partner improve health outcome people need putting special focus improving health people low middleincome country around globespecifically tackling several tenacious diseasestuberculosis diabetesthat growing rapidly part world 13 lilly 20112012 corporate responsibility update enhancing access medicine 01 02 03 03 04 05 06 07 08 09 approach expanding business community access medicine mustplay vital role lilly committed taking thoughtful step meaning map country visit wwwlillycom addressing complex problem fully enhance access medicine improve health responsibilityaccesstomedicinespagesincreasing underserved population however realize accesstomedicinesaspx clear writing check single organization solve problem related donating product alone doesnt access medicine therefore focus effort lasting impact growing believe greatest impact truassist body evidence demonstrates pricing medicine lilly dedicated discovering developing company engages innovative medicine help improve people life lilly strives engage government throughout world offer product sustainable price commitment includes offering assistance people may partner area able afford medicine 2011 announced affordable local population price prescription company deep expertise lilly truassist easytouse onestop resource medicine like product differ country country difference currency value access lillys existing patientassistance program vested interest society market dynamicsor may kept artificially low benefit company government price control lilly advocate policy support differential pricingie charging lilly participates partnership prescription enhances performance different price based purchaser ability pay assistance pparx pharmaceutical industry learn work area see page 09 program make easier physician john c lechleiter phd patient access patientassistance program lilly chairman president chief executive officer patent least developed country many developing country lilly seek 250000 patient received help enforce patent medicine contribute program 2011a 12 percent increase making medicine accessible example previous year program cover range lilly seek patent least developed country health condition including mental health diabetes ldcs defined united nation result cardiovascular disease men health osteoporosis generic manufacturer free produce provide oncology growthhormone disorder market generic version medicine country value assistance provided program totaled 500 million 14 lilly 20112012 corporate responsibility update enhancing access medicine 01 02 03 03 04 05 06 07 08 09 lilly global health innovation campaign lilly committed partnering closely local government organization identify promote healthcare solution reduce burden diabetes multidrugresistant tuberculosis mdrtb 2011 unveiled lilly global health innovation campaign aimed improving health underserved population campaign encompasses two lillys signature program lilly ncd partnership lilly mdrtb partnership create positive longterm change lilly together partner focused researching piloting new model health care based sophisticated research detailed data collection immediately benefit patient reporting sharing data lesson learned locally globally advocating informing key stakeholder program finding encouraging adoption proven solution 15 lilly 20112012 corporate responsibility update enhancing access medicine 01 02 03 03 04 05 06 07 08 09 lilly ncd partnership noncommunicable disease noncommunicable disease ncds also known mexico afflicting nation community chronic disease include cardiovascular disease mexico lilly work carlos slim health institute family around world diabetes cancer chronic respiratory disease evaluate enhance casalud worldclass primary developing country disease havent garnered care clinic training program centered comprehensive vulnerable bearing attention tuberculosis hivaids ncd diagnosis care lillys role research burden malaria yet together ncds account 63 program demonstrate casalud increased percent death worldwide fourfifths number diagnosed patient andby ensuring early intervention placehas improved prolonged john c lechleiter phd death occur low middleincome country life also measuring cost benefit early lilly chairman president chief executive officer thats lilly created lilly ncd partnership 30 million commitment five year fight growing diagnosis management diabetes sharing burden noncommunicable disease research data program reporting advocacy south africa company government single institution johannesburg africa secondlargest city lilly solve ncd challenge alone take new way working project hope establish hope thinking collaboration unprecedented centre fiveyear communitybased project scale designed identify comprehensive sustainable address care gap people risk already living approach patient care lilly ncd partnership diabetes south vast rural stretch focus initially diabetes targeted community eastern cape partner donald wood india mexico south africa expansion foundation building success homebased brazil late 2012 hiv program include improved diabetes care india india lilly joined force public health foundation india population service international project hope implement comprehensive program address low level diabetes awareness uncoor dinated healthcare service project cover 400000 people two location sonipat near delhi vizag east coast includes awareness activity healthcare provider training patient care 16 lilly 20112012 corporate responsibility update enhancing access medicine 01 02 03 03 04 05 06 07 08 09 lilly mdrtb partnership recognizing spread multidrugresistant eli lilly company foundation foundation india tuberculosis mdrtb could halted medicine recently made fiveyear 20122016 30 million partnership training program reach pharmacist alone lilly launched lilly mdrtb partnership commitment support organization lilly nurse rural healthcare provider private practitioner 2003 according world health organization mdrtb partnership commitment mark several state including andhra pradesh maharashtra 650000 people currently infected mdrtb third final phase focus tamil nadu west bengal far diagnosed treated providing training healthcare provider pro russia almost 10 year lilly mdrtb partnership fessional health worker nurse doctor russia partnership research benefit partnership worked world leading informal caregiver community volunteer training healthcare provider demonstrate positive organization battle mdrtb lillys initial contribution improving supply access safe effective effect wellmanaged treatment care included 120 million cash medicine advocacy tool highquality mdrtb drug end 2010 health mdrtb patient work take place technology focused prevention diagnosis less 16 percent estimated mdrtb patient region saint petersburg voronezh treatment patient mdrtb nearly 20 million globally received drug needed mari el republic additional fund lilly tb drug discovery initiative accelerate discovery new drug treat tb foundation work partner global local level specific focus partner four south africa weve achieved lot country carrying highest burden mdrtb china south africa partnership support national weve transferred manufacturing technology seven india russia south africa information government plan expand decentralize mdrtb company increase availability mdrtb medicine please visit wwwlillymdrtbcom diagnosis care enhancing healthcare provider capacity investigating current healthcare weve trained 100000 healthcare professional china training program variety setting identifying better recognize diagnose treat mdrtb partnership train medical professional six work best replicated well pinpointing weve distributed guideline toolkits need action chinese province namely fujian hebei jiangxi 45000 hospital clinic liaoning sichuan xinjiang mdrtb prevention weve reached million people highrisk communi screening tie innovative public awareness campaign 17 lilly 20112012 corporate responsibility update enhancing access medicine 01 02 03 03 04 05 06 07 08 09 improving access drug treat mdrtb currently far mdrtb patient receive institute medicine iom drug need estimated fewer 46000 research project people worldwide receiving verified treatment partnership sponsoring global effort iom drug mdrtb estimated 650000 infected assemble leading expert mdrtb evaluate mdrtb range issue contributes challenge effort increase supply mdrtb medicine drug access including poor forecasting product need vet new idea improve access medicine limited laboratory capacity diagnosis underperforming iom convene two meeting current leading thinker market pricing inadequate resource strengthen help ensure mdrtb remains global health priority system needed manage complex treatment regimen required patient partnership work area focus developing new thinking innovation summit translated measureable action partnership hosted innovation summit 2012 bring supply chain expert together entrepreneurial collaboration mdrtb advocate thinker inside outside healthcare field look access issue innovative way summit initiative pull together leading expert stakeholder output includes 12 actionable idea addressing barrier field analyze bottleneck access propose best idea pursued collabora solution patient access affordable tions organization working tb field qualityassured treatment 18 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 04 developing innovative medicine 136 year lilly discovered developed acquired innovative new medicine address key unmet medical need worldwide take molecule discovery clinical development commer cialization requires perfect combination promising molecule specialized scientific expertise sufficient funding stage development use medicine lilly strives maintain highest standard ethical behavior begin bioethics program guiding principle reflected commitment protect human right wellbeing clinical research subject well welfare animal research subject 19 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 innovation start support commitment speeding lilly innovation fellowship award delivery innovative new medicine patient lilly innovation fellowship award foster postdoctoral launched innovation start global initiative career development selection highly innovation start foster innovation quality innovative research proposal lilly created science institution internal external program broaden postdoctoral scientist training program designed enhance basic science harness experience better prepare broad range innovation aid discovery development career including pharmaceutical industry innovative new medicine patient worldwide award establish precompetitive academic industry two key component initiative include lilly training partnership postdoctoral fellow research award program lilly innovation academic mentor paired lilly scientist provide fellowship award lilly scientist industry resource enable advancement collaborate academic researcher project postdoctoral scientist research proposal 2012 aid advancement lillys pipeline future lilly innovation fellowship award invitation applicant academic research center lilly research award program united state united kingdom lilly research award program brings together diverse group scientist worldwide effort advancement research important therapeutic area lilly expertise including neuroscience cancer diabetes immune system disorder others 20 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 biopharmaceutical rd highly lilly collaborates help complex formation accelerate development new medicine transcelerate biopharma inc underscore belief lilly often midst clinical study head research development member need competitor medicine comparison company compose tbis board director including way address costly timeconsuming task one jan lundberg phd executive vice president science industrywide challenge vital determining molecule safety efficacy technology president lilly research relation currently available treatmentsespecially laboratory member tbi identified clinical coming together sharing today environment regulator demanding study execution initiative initial area focus best practice ultimate differentiation currently approved medicine five project selected group funding pharmaceutical industry could come together development member company agreed goal accelerating pace develop timely costeffective solution equally share financial commitment personnel information innovative medicine getting necessary comparator medicine risk area including clinical study reach patientswhether development shared user interface investigator new industrywide coalition transcelerate biopharma site portal lilly others inc tbi formed solve challenge others mutual recognition study site qualification training arent possible one pharmaceutical company development riskbased site monitoring approach jan lundberg phd address tbi represents firstofitskind standard executive vice president science technology development consortium pharmaceutical company president lilly research laboratory collaboratingin precompetitive environment lilly development clinical data standard join nine partner founding member tbi establishment comparator drug supply model including abbott laboratory astrazeneca boehringer ingelheim bristolmyers squibb glaxosmithkline johnson johnson pfizer roche sanofi 21 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 bioethics bioethics pioneer lilly bioethics program designed address lilly bioethics advisory committee lilly bioethics network lilly one first pharmaceutical increasingly complex ethical challenge global pharmaceutical research development rd beac crossfunctional volunteer committee company establish standing bio today fastpaced biotechnology environment comprising seniorlevel employee area within ethic committee 1999 program program promotes ethical research drug development outside rd including medical patient safety 2008 today fulltime professional safeguard integrity scientific process discovery research veterinary resource legal corporate affair global brand development membership also staff help promote ethical practice protects patient right wellbeing includes two external academic bioethicists member throughout lilly operation 2012 promoting responsible human research take basic training bioethics provide advice bioethics 17 senior leader sat consultation offer input company bioethics purpose lilly bioethics program assist lilly bioethics advisory committee project development lillys official employee identifying addressing bioethical position bioethics issue ben informal issue related lillys rd activity program voluntary virtual community 100 lilly independent organizational unit within lilly employee interested developing fulltime professional staff senior leader knowledge skill bioethics vice president bioethics committed promoting excellence ethic support program also come lilly bioethics advisory committee position consultation beac lilly bioethics network ben development lilly bioethics program comprises four core activity establishing articulating company position bioethics key bioethics issue lilly consulting lilly staff conducting internal education training bioethics education collaboration contributing internal collaborative project inte training grate bioethics rd operation well external project contribute advancement field bioethics relates pharmaceutical application 22 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 lillys approach bioethics pharmaceutical research manufacturer informed consent america principle conduct clinical trial one key aspect protecting research participant bioethics framework human biomedical research addition applicable law regulation informedconsent process designed respect lillys ethical commitment beyond legal compliance country country study conducted individual autonomy protect individual lilly strives maintain highest standard ethical choosing location worldwide conduct clinical trial freedom choice patient volunteer wish behavior aspect company business consistent lilly considers local prevalence disease participate lillysponsored research informed brand 2010 provide researcher guiding study medical research capability verbally writing purpose method principle practical tool lilly developed bioethics candidate institution possible risk benefit study well fact framework specifically describe evaluate ethic free withdraw study addition lilly work local ethic committee developing conducting analyzing disclosing result time reason decision volunteer andor health authority appropriate ensure study involving human subject framework study must individual choice free undue conducting proposed research location incorporates company value ethic principle widely influence might persuade person consent scientifically ethically justified decision recognized global guideline scholarly literature greater reasonable risk help ensure take consideration lillys policy promise payment money lilly bioethics program member employ bioethics risk benefit research participant reward large unduly influence framework conduct ethical analysis answer relevance research local health need prospective subject decision individual consent consultation question develop bioethics position participate study documented signature potential research yield important agreement case individual protecting research subject right clinical trial scientific advance capable giving informed consent including child lilly place paramount importance safety intent register drug host country consent legally authorized representative may wellbeing individual research participant obtained behalf individual provided bioethics framework basis single global study participant provides assent participate standard lilly applies conduct clinical trial worldwide practice consistent 23 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 summary lillys position use placebo control lilly global quality lilly belief use placebo control stem cell research organization development new medicine scientifically lilly belief scientific potential stem cell valuable ethically justifiable provided use research also acknowledges conflicting lillys global quality team independent placebo meet several key condition decision view ethic using stem cell derived conduct placebocontrolled trial made careful organization within lilly comprising certain source support scientific innovation respect analysis scientific ethical consideration risk 2400 individual including scientist human life respect stakeholder view lilly us research participant local regulatory requirement stem cell derived animal pharmacist technical quality human source appropriate informed consent professional team involved compassionate use investigational medicine andor assent obtained little risk compassionate use refers authorized use entire lifecycle molecule develop harm sample donor medicine still investigational phase working across phase drug develop development typically treat serious lifethreatening human biological sample ment team goal provide effective disease lilly develops medicinespecific guideline human biological sample long utilized guidance quality oversight collaborating request may considered general lilly preclinical clinical pharmaceutical research authorizes compassionateuse program based colleague research development play increasingly important role posthuman investigational medicine phase development benefitrisk manufacturing assure regulatory genome era specifically dna sample essential profile probability timing regulatory approval understanding genome variation affect lillys quality standard control affected pharmaceutical intervention information lilly bioethics visit followed individualized information extracted wwwlillycomresponsibilitymedicinedevelopment dna sample lilly commits protecting using pagesbioethicsprogramaspx data derived sample responsible manner minimizes potential physical dignatory discriminatory stigmatizing harm 24 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 lilly quality putting integrated global quality system patient center quality process fully integrated every stage drug development design phase everything delivery phase monitoring phase lilly known superior qualityin clinical trial product information provide customer producing quality medicine chief responsibility protects bond trust lilly customer every day work make sound decision consistent current regulation science best interest patient goal always carefully listen patient customer respond continuous improvement meet expectation quality lillys hallmark quality team update manages lilly quality design deliver monitor system providing foundational quality requirement clinical development safety efficacy data safety process throughout product development cycle product development manufacturing distribution product complaint integrated structure standard business process organizational management control lilly quality market research product information patient experience system designed assure highquality medicine information get every patient every time system harmonizes quality approach needed among internal external contract manufacturer lilly medicine provides overall quality direction across company ensure able meet standard lillys quality organization provides onsite support well conduct annual riskbased audit plan oversee internal lilly external partner operation audit result provide u knowledge need continue make improvement quality control system 25 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 global manufacturing diversity clinical trial 6000 individual 23 site work lillys study must designed conducted due minority population historically consistently global manufacturing organization group consideration relevance study human underrepresented clinical trial result responsible company safe production animal health advancement knowledge important information medicine work continuous supply highquality medicine patient animal must provided living condition minority population always available issue worldwide global manufacturing partner lillys appropriate specie contribute critical patient response medicine business area help deliver value health wellbeing vary ethnicity lifestyle genetic background commitment scientific excellence quality cost personnel care animal design help boost enrollment diverse population trial effectiveness integrity maintain continuous conduct animal study must appropriately qualified make trial accessible minority community improvement manufacturing consistently invests trained lilly partnered professional advocacy people process technology needed ensure animal must treated humanely pain organization launch awareness campaign set quality people expect select lilly product distress eliminated minimized goal across therapeutic product line achieve greater diversity among patient enrolling new clinical animal testing performed consideration trial since 2008 introduced nearly 300 new animal care use three r replace animal whenever scientifically clinicaltrial site united state location valid acceptable alternative exit reduce minority patient population 25 percent lilly believe moral ethical scientific number animal used refine procedure responsibility ensure welfare animal used minimize distress outreach included multiple presentation purpose company policy standard need diversity clinical trial organization study involving animal must designed regarding use animal based upon u national medical association nma national conducted accordance applicable government principle utilization care hispanic medical association nhma american country local regulatory guidance vertebrate animal used testing research training medical association ama education network intent lilly facility accredited advance cancer clinical trial enacct ama assess potential safety toxicity efficacy association assessment accreditation commission end health care disparity compound human use lilly researcher must laboratory animal care aaalac aaalac provides american association cancer research aacr conduct vivo study acceptable alternative independent review confirmation appropriate also conducted several national regional local exist conducting assessment animal care use united state lillys animal panel reaching journalist advocate healthcare personnel must comply policy care use committee approve oversee animal provider concerning healthcare disparity following principle use similarly lillys ethical committee review animal clinicaltrial diversity strategy usage united kingdom 26 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 breaking barrier diverse clinical trial help address barrier access trial clinicaltrial diversity strategy includes following activity translating patient material spanish providing physician education material include background different need distinct patient group partnering advocacy organization raise awareness health disparity need diversity clinical trial actively recruiting investigator diverse patient population 27 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 76 36 lilly diversity clinical trial united states10 need diverse representation clinical trial gain insight making medicine effective people use lilly aim better match demographic composition clinical test group disease prevalence rate general population site west site northeast 37 site midwest 95 site southeast 26 site southwest 5 site alaska hawaii 20 site puerto rico site 2012 10 diverse clinical site defined clinicaltrial site patient population medical practice necessarily enroll trial 25 percent noncaucasian 28 lilly 20112012 corporate responsibility update developing innovative medicine 01 02 03 04 05 06 07 08 09 tailored therapy educating patient lillys goal help improve historically medicine one size fit regulatory agency approves medicine individual patient outcome increasingly changing tailored therapeutic concluded overall public medication medicine dont work promise deliver greater precision higher value benefit outweigh risk condition outlined improved outcome individual patient using product label still accurate uptodate safety everyone need variety approach detect meaningful difference information critical healthcare provider understand medicine within patient population identify right drug patient best decide medication right dose patient used lillys role risk management center work safety profile tailored therapeutic part technical using helping healthcare provider make informed decision patient likely take medicine used emerging technology capability pharma monitor patient potential adverse event culture ceutical industry move toward better predictable patient outcome also strategy communicate patient proper use strongly influence patient medication january 2010 lilly launched patient enhancing social value medicine medicine safety website wwwlillycomproductspatientsafety define health perception lifestyle potential risk benefit tailoring allows u use realworld data information input educate key external stakeholder role choice healthcare seeking pharmaceutical industry fda physician patient closest patient develop therapy offer play ensuring medicine safe effective behavior need understand value individual society relevant cultural difference impact patient outcome global patient safety coleman obasaju md phd lillys global patient safety organization team senior medical director lilly oncology 300 individual including physician pharmacist global leader diversity clinical research nurse drugsafety professional group lead company effort report adverse event continuously monitor safety lillys product entire lifecycle including identification change benefitrisk balance 29 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 05 supporting strong workplace practice century ago colonel eli lillys vision commitment patient employee community set strong tone company continues today business prospered 136 year peoplepeople talent innovation passion making difference finding treatment stubborn disease people whose talent matched generosity people strong value determination prevail regardless challenge 30 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 developing workforce colonel lillys valuesintegrity excellence respect business effective leadership essential freedom association peoplecontinue shape practice strive created program activity designed build recognize importance freedom association provide employee engaging rewarding working leadership skill longterm responsibility ensure workplace respect right employee environment built foundation trust believe lilly talent pipeline future lilly join association choosing lilly interacts created workplace fair labor practice think many year advance plan drug pipeline work council union several country outside employee respected contribution need people pipeline united state support body work pharmaceutical company mission effective employee collaboration critical lillys productively vast majority worker make medicine help people live longer healthier success work engage employee globally covered traditional collective active life employee essential u foster promote teamwork even challenging bargaining agreement country accomplishing mission early leader business environment believe important operate government mandate working condition company recognized action speak louder invest employee development program salary increase minimum wage bonus wordsparticularly employee concerned connecting heart abroad program invite 200 number weekly working hour vacation time intellectual capital may modern term employee year volunteer company time overtime rate vary country follow even early lilly management understood two week 10 country people lack access mandate wherever required several knowledge skill lilly people company basic resource including quality health care affiliate employee council meet monthly important asset management discus workforcerelated issue directly impact company policy today offer workforce competitive compensation privacy concern organizational change benefit package provide wide variety opportunity personal growth aim create first industry formally environment employee balance work implement policy protect privacy personal life responsibility provide employee employee genetic information opportunity build career reward personally goal ensuring information cannot professionally helping company advance used discriminate employment vision improve patient outcome benefitrelated decision 31 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 workplace award frequently ranked one best company world work recent recognition includes following top 50 top 100 best place top 25 company diversity best place work work global company leader lilly ranked 29th 587 best place work hall corporate equality index lilly ranked among top 25 company completed fame working mother magazine 2009 2011 aon hewitt diversityinc survey 2012 19952012 perfect score 100 20062012 human partnership fortune second time lilly right campaign index measure rbl group made top 50 list organization effort toward creating equitable environment lesbian gay bisexual transgender lgbt employee top company best class top working family employer asian pacific company american professional finalist lilly cited model workplace flexibility employee workplace executive woman asia society 2012 diversityinc 2012 national association female executive 20092012 excellence award finalist equal 2012 32 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 top company working family 2012 diversityinc named lilly top company globally lilly offer number program varying working family diversity assessment firm honor location assist employee maintaining worklife select group company year leadership flexibility include flexible work arrangement innovative solution demonstrate next wave personal leaf onsite health servicesfitness center diversitymanagement success particular lilly well onsite child care credit union dry cleaner honored model workplace flexibility family support program employee lilly flexibility able recruit retain best talent competitive marketplace preparing changing environment reducing cost related lilly recognizes critical importance absenteeism employee flexible work schedule worklife integration tool address lead reduced stress better health stronger diverse need expectation lifestyle focus work overall flexibility lead improved level work style employee allowing employee engagement drive productivity effective john c lechleiter phd lilly chairman president chief executive officer 33 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 diversity inclusion u workforce 2011 47 lilly embracing diversity core longheld disparity address unique healthcare need value respect people lens community diversity commitment extends understand respond unique need full spectrum business including 53 million individual depend medicine clinicaltrial strategy supply chain proud diversity essential role play helping u accomplish mission making medicine working embed diversity within culture lilly integrating every aspect help people live longer healthier active life businessfrom marketing practice hire creating maintaining nondiscriminatory work employeesand seeing good result example global workforce 2011 environment key priority u lilly code twice named diversityincs list top 46 business conduct call red book 50 company diversity widely recognized requires employee behave workplace free improper conduct harassment premiere thirdparty diversity assessment united state 2012 list lilly ranked 29th 587 inappropriate form discrimination company completed survey diversityinc also 54 red book see page 08 lilly employee cited lilly 2012 model workplace flexibility embracing diversity mean understanding respecting employee see page 33 valuing difference including limited recently stepped diversity inclusion race religion gender sexual orientation work style effort visible businessbased commitment national origin age focus people area global organization minority employee 19 u workforce lilly work attract retain talented employee manufacturing arena example promoting bring varying perspective skill need operate global level diversity foster creativity effort banner make unique make u stronger developing adopting formal 7 3 creativity drive innovation innovation lead business case diversity inclusion based better patient outcome enhanced business success notion every person every decision count asian latino without diverse idea simply cannot remain viable also increased leader accountability rapidly changing environment partner advocacy group professional society developing diverse talent senior leader perfor mance objective focusing mentoring careerpath 7 2 community organization public private healthcare planning woman diverse employee globally administrator others help reduce health african american 34 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 fighting inclusion health safety wellness woman important proactive working legal system ensure protecting health safety employee customer since make community operate open welcoming coming perspective large one foremost priority consistent majority healthcare decision company value respect people 2008 lilly indiana employer global diverse workforce established goal reduce employee injury rate 50 family many lillys employee scientist medical doctor percent end 2013 compared 2007 see data understand meet pharmacist engineer critical page 37 meet injury reduction target weve research development new medicine recruit focused situation pose greatest risk diverse need need make worldwide highly skilled people intensely employee worldwide slip trip fall motor sure everyone opportunity competitive environment excellent employee vehicle collision ergonomic risk ability thrive home state indiana dependent contribute lead goal aggressive aspirational environment welcoming accomplished hoped would change continue raise voice opposition workplace behavior reduction severity eiry robert md proposed indiana constitutional amendment ban injury across global operation end chair lilly womens network vice president lilly biomedicine samesex marriage civil union lilly view 2011 reduced rate serious injury proposed amendment harmful overreaching losttime injury 24 percent since 2007 motor addition restricting marriage civil union could vehicle collision rate per million mile meanwhile pose challenge extension domestic partner dropped 7 percent time period believe diversity critical benefit amendment harmful lilly seek despite solid progress currently track attract retain great talent detrimental meet 2013 reduction innovation inclusion indiana effort life science leader injury prevention effort impeded several diversityinc list top requires critical mass worldclass talent private sector academic institution lilly challenge example health safety program 50 company diversity matured facility emerging market weve prepared continue strong advocacy seen consistent reporting workrelated injury great honor validation unfair language incorporated indiana highest legal document illness globally mean serious injury effort create environment rate declining quickly would like innovation flourish shaun hawkins chief diversity officer 35 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 2013 goals11 tonot people getting hurt early formation wellness productivity injury reported greater integrity want team realized mission organization location report injury happen needed mirror call lilly promise part 50 learn incident help avert similar promise commitment making medicine episode future help patient live longer healthier active life need employee family ergonomic improvement key priority u recognition experience individual recent year weve focusing way adjust stress issue challenge others job fit employee rather way reduction serious injury rate around integrating ergonomic design criterion people hear term wellness often capital improvement project within workplace think physical aspect health fitness routinely host training session employee fulfill promise employee thought 50 type job category 2011 lilly invested million important broaden view wellness promoting dollar capital project professional service multiple dimension contribute personal implement employee idea improving wellbeing physical financial social career ergonomic condition office laboratory sale fleet community 2012 launched fit life set manufacturing plant tool resource help employee better reduction losttime injury rate manage health also identify thing june 2011 lilly made renewed investment contribute healthy active life wellbeing employee launch new fit life offering include following free 50 global compensation benefit program including health screening wellbeing assessment plan formation wellness productivity team health coaching access fitness center team direct responsibility u wellness strategy worklife operation health management promotion 2011 continued push toward reducing rate employee activity well leaf disability motor vehicle collision involving sale team similar wellness team several spend much time road reduction motor vehicle collision international location motor vehicle safety program thousand lilly sale representative received behindthewheel training 11 goal based 2007 baseline serious injury rate defined number workrelated injury illness require medical treatment beyond immediate first aid per 100 employee working fulltime year losttime injury rate reflects severity serious injury equal number serious injury result employee missing least one day work per 100 employee working fulltime year 36 lilly 20112012 corporate responsibility update supporting strong workplace practice 01 02 03 04 05 06 07 08 09 better defensive driver emphasize serious injury rate12 losttime injury rate motor vehicle collision rate importance maintaining safe operating distance per 100 employee day workday per 100 employee collision per million mile driven vehicle avoiding distraction texting talking cell phone impede 2007 144 2007 062 2007 1110 focused driving 2008 118 2008 059 2008 1206 pleased report workrelated employee fatality 2011 lilly continues 2009 092 2009 038 2009 1117 emphasize prevention catastrophic event weve 2010 096 2010 041 2010 1048 recently begun identification assessment management everyday workplace risk done incorrectly 2011 109 2011 047 2011 1028 sequence result serious injury death 2013 goal 072 2013 goal 031 2013 goal 550 expect standardize evaluation across company next several year want employee healthy productive lilly life outside work robust serious injury accident category losttime injury accident category management system rigorous health safety program emphasis employee engagement serve cornerstone success reducing injury 37 21 sprainstrainergo risk sprainstrainerg 21 17 21 15 24 37 sliptripfall sliptripfall 27 38 motor vehicle 27 collision 38 24 motor vehicle collision 15 21 17 sprainstrainergonomic risk sliptripfall motor vehicle collision 12 2013 goal 2007 baseline three workplacerelated metric health safety data prior year adjusted slightly due updated data collection 37 lilly 20112012 corporate responsibility update lilly around world 01 02 03 04 05 06 07 08 09 06 lilly around world lilly robust history community involvement believe make impact extends far beyond medicine make many donationsincluding provided eli lilly company foundationfocus improving access medicine quality health care company donates substantial amount product cash every year employee volunteer time skill score charitable cause program animal health division elanco focus hunger relief developing technology needed feed growing world population elanco committed sustainably end hunger 100000 family globally partner ship nonprofit heifer international 38 lilly 20112012 corporate responsibility update lilly around world 01 02 03 04 05 06 07 08 09 lilly global community giving 30 million 6500 800 family helped thousand vial philanthropic insulin commitment lilly mdrtb elancos hunger life child partnership commitment subsaharan africa asia china russia south africa india zambia china indonesia south america publicprivate initiative work elanco animal health division committed donating tackle multidrugresistant tuber committed end hunger 100000 800000 vial insulin culosis highburden country familiesor 600000 individualsglob international diabetes federation 2011 phase iii launched 30 ally 2025 partnership life child program million philanthropic commitment heifer international end 2011 2008 2013 end 2011 five year eli lilly nearly 6500 family helped lilly donated nearly 350000 vial company foundation help child access diabetes treatment 30 200 lilly ambassador 850 million thousand five year contributed charitable contribution disaster relief global day service lilly ncd partnership connecting heart abroad global giving project worldwide gave approximately 25 annual global day service brazil india mexico asia africa central guatemala haiti thailand 2011 gave 590 million donation 2011 among largest singleday south africa south america turkey zambia million charitable contribution following natural disaster volunteer initiative u including cash product company 2011 logged lilly ncd partnership launched signature connecting heart eli lilly company foundation inkind donation organization 98000 volunteer hour 2011 provides 30 million abroad program sends 200 lilly nearly 14000 lilly employee around world 40plus country indianapolis five year fight rising burden ambassador year twoweek contributed 850000 planted 3000 tree noncommunicable disease ncds assignment provide assistance support 800 global giving applied 500 gallon paint developing nation developing community project country around world program captured page represent biggest philanthropic initiative detail community effort found 2010 cr report 39 lilly 20112012 corporate responsibility update lilly around world 01 02 03 04 05 06 07 08 09 community giving united state 25 million 240000 2000 20000 educationfocused grant additional meal teacher supported pound watermelon improve public education served 2011 financially strategically grown harvested mind trust grant childhood hunger initiative stem program golden harvest indianapolis indianapolis indiana augusta georgia largestever educationfocused grant 25 elanco actively engages support lilly financially strategically supporting elanco employee grew harvested million mind trust helping improve indianapolis childhood hunger initiative implementation indiana science initiative 20000 pound watermelon 6000 pound public education underserved child elancos help 240000 additional meal home state supporting 2000 teacher pumpkin land owned managed elanco indianapolis program teach served 2011 serving 40000 student 2011 lilly augusta benefit golden harvest local food bank america novel charter school incubator science coach programa volunteer program reinforcing inquirybased learningtrained 120 lilly scientist matched 120 teacher marion county 40 lilly 20112012 corporate responsibility update engaging patient 01 02 03 04 05 06 07 08 09 07 engaging patient understand health challenge patient family face provide hundred million dollar product donation year help product contribution tell part story lilly work go beyond medicine help patient improve health manage disease believe informed patient better participant care achieve better health outcome patient access less information 41 lilly 2011 corporate responsibility 41 lilly 20112012 corporate responsibility update engaging patient 01 02 03 04 05 06 07 08 09 supporting patient support partner numerous local oncology canvas type 1 diabetes national organization including addressing lilly oncology canvas expression cancer collaboration disney multicultural health disparity improve patient journey art competition exhibition honor child diagnosis type 1 diabetes t1 care united state example minority group journey people face confronted cancer whelming caregiver often question ever often suffer heightened rate certain disease diagnosis biennial competition invite individual able get family back kind daily including diabetes one area therapeutic diagnosed type canceras well family routine parent child may feel diagnosis focus u preventionrelated intervention friend caregiver healthcare providersto end future hope dream customer include material printed multiple language express art narrative lifeaffirming understanding served foundation lilly traditionally underserved community change give cancer journey meaning diabetes business unit partner one everyone need medicine able result compelling art collection provides powerful brand world disney launched 2011 get united state lilly truassist insight wide range emotion experienced collaboration offer healthcare provider family wwwlillytruassistcom provides access product touched cancer variety fun informative book child eligible patient several patientassistance tweens including coco first disney character program majority product donation face diabetes campaign t1 lilly disney also offer dynamic content made truassist serf umbrella provides support practical everyday tip family fearless african american connected program lillys many patientassistance effort t1 response customer date empowered face diabetes campaign grassroots program typically focus core area expertise overwhelmingly positive collaboration movement help african american overcome key including cancer diabetes mental illness support expanded multiple international market barrier success living type 2 diabetes african many initiative including following example american disproportionately affected disease according american diabetes association african american united state 18 time likely diabetes nonhispanic white onequarter african american age 65 74 disease supported lilly face diabetes campaign offer program tool help people make lifestyle change manage disease 42 lilly 20112012 corporate responsibility update engaging patient 01 02 03 04 05 06 07 08 09 diabetes conversation reintegration award scholarship created healthy interaction collaboration founded 1997 lilly reintegration scholarship international diabetes federation lilly diabetes program help person bipolar disorder sponsor diabetes conversation program featuring schizophrenia related schizophreniaspectrum conversation map education tool innovative disorder providing funding tuition lab fee education method us unique visual approach book may pursue achieve educational facilitate interactive group participation empower vocational goal independent judging panel people diabetes become actively involved comprised psychiatric care professional review managing disease education tool available application chooses qualifying scholar 35 language launched 110 country since 2008 lilly better health lilly better health patientfocused resource camp care package available community health advocacy organization decade lilly one public private healthcare provider policymakers largest provider insulin glucagon educational others interested improving health wellbeing material volunteer scholarship special guest community lilly better health includes diabetes camp comprehensive lilly camp website conference exhibit printed material care package 2011 104 diabetes camp participated reach ten thousand customer directly camp color program arttherapybased year community event program healthcare initiative child requesting camp received 24 conference offering valuable education material million insulin product 19000 educational interactive assessment tool variety health topic bookpacks lilly also provides camp tuition support 2010 distributed 450000 patienteducation partnership american diabetes association resource individual organization website updated 2011 spotlight lilly partnership program focus wellness prevention disease management offer ondemand access health education material many lilly better health resource available english spanish select tool mandarin 43 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 08 fostering environmental sustainability medicine make require use valuable resource including energy water raw material operate business today longlasting impact lilly take broad approach understanding managing envi ronmental impact across product life cycle committed conducting business patientcentered environmentally socially financially responsible manner 44 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 18 32 commitment approach performance meeting environmental goal demonstrates commitment reduce million million environmental footprint believe implementing innovative costeffective sustainable solution return realized lilly 2011 approximate cumulative reduction powerful ongoing source business value project implemented far energy spending 20082011 helping section cover broad range environmental energy waste natural resource lilly avoid nearly 240000 metric ton activity approach management system reduction fund co2e emission work addressing environmental issue across business performance data example illustrating progress 143 million liter amount water saved per year 10 number site globally reported zero speke united kingdom manufacturing landfill status 201113 facility following enhancement antibiotic production process 13 site may achieve zero landfill status less 05 generated waste sent landfill 45 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 life cycle approach stage pharmaceutical product life cycle includes distinct environmental health safety impact offer opportunity research development material natural resource manufacturing improvement graphic provides consider environmental factor lilly customer government worldwide measuring reporting reducing lillys overview work reduce potential earliest stage design development increasingly focused material environmental impact manufacturing impact operation design environment initiative include chemical used make product work central company environmental green chemistry environmental productrisk consume less material water sustainability program manufacturing assessment environmental devel natural resource possible health safety environment hse com opment review process evaluate potential mittee oversees compliance applicable environmental issue opportunity hse regulation policy procedure scaleup medicine production standard making certain manufacturing level see page 49 drive continuous improvement throughout information manufacturing organization see page 51 information sale marketing product transport packaging product use product endoflife lilly continually work improve fuel lillys packaging guidelineswhich cover lilly committed understanding medicine intended used efficiency sale force vehicle meet area reducing material use using potential effect pharmaceutical product entirety patient unused medicine internal target reduce overall fleet lowerimpact material enhancing environment well human cannot recycled result model fuel use 10 percent globally 2013 lilly packaging recyclabilityhelp u incorporate support using sciencebased evaluation take back reuse recycling sector sale marketing office worldwide weve sustainability consideration packaging assess reduce environmental risk designed capture value product established project reduce energy use decision track greenhouse gas pharmaceutical product use applied industry increasing employee environmental ghg emission product transportation collaboration industry partner academic working customer partner awareness action distribution vendor work researcher regulatory agency ensure costeffective approach available reduce impact see page 50 continually work understand product endoflife disposal balance information proactively address potential impact environmental risk patient privacy legal production distribution use compliance security see page 50 disposal product see page 50 information information 46 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 manage environmental issue hse governance audit lillys formal hse governance structure ensures year audit significant portion site policy standard hse issue management integrated companywide globally assess performance following protocol several policy standard define commitment global hse committeewhich includes senior outlined hse standard use riskbased guide effort area executive key area businessensures approach determine site audit reassess proper oversight play central role monitoring site every one five year include external global policy health safety corporate performance ensuring continuous well internal auditor audit conducted environment set environmental expectation related improvement global hse lead team work closely compliance environmental protection global hse committee set appropriate lillys environmental goal people operation metric goal assess company performance setting driving toward communicating progress environmental standard provides detailed oversee compliance hse regulation policy toward hse performance goal central hse requirement establishes core governance procedure standard globally manufacturing management approach requirement manage significant environmental hse committee support effort drive energyrelated aspect operation 2008 lilly established six hse performance goal ongoing improvement throughout manufacturing minimize impact environment see page management system standard verification organization executive lead team 48 reduce employee contractor injury corrective action standard define requirement business group well lilly research laboratory goal follow earlier set achieved ahead ensure compliance lilly hse standard applicable lilly corporate center manage governance target date demonstrating drive continuous regulatory requirement external hse hse area improvement see page 37 progress toward standard corporation subscribes health safety goal global engineering standard govern many management system environmental aspect operation lilly business unit hse management system energy use ghg emission aligned management system standard consistent thirdparty standard iso 14001 product stewardship standard provides ohsas 18001 american chemical council systematic way manage product process risk responsible care management system rcms supply chain operation global hse management system also certified use product rcms several lilly facility obtained certification external standard 47 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 2013 goal 2007 baseline 15 15 energy waste natural resource reduction fund making capital investment technology physical plant operation substantial positive envi ronmental impact however project compete reduction energy intensity14 reduction greenhouse gas emission intensity1415 funding essential project facility progress 201116 address challenge established energy waste 17 reduction progress 201116 natural resource reduction fund fund help 16 reduction pay capital project facility globally promotes development environmentally superior efficient technology bestpractice sharing across facility 25 40 amount spent decreased substantially 2011 see table due readily available capital site level shortage needed human resource implement project however fund ontarget invest 2 million 2012 2011 lilly realized return 18 million project reduction water intake17 reduction waste landfill1718 implemented far achieved 2009 four year early achieved 2009 four year early energy waste natural resource progress 201116 progress 201116 reduction fund expenditure 32 reduction 66 reduction million updated goal 2010 baseline updated goal 2010 baseline reduce water intake 5 2013 reduce waste landfill 20 2013 65 57 14 per square foot facility space 15 goal cover lillys scope 1 scope 2 emission 41 16 following world resource institute guidance progress toward environmental goal reported adjusted basis accounting merger acquisition divestiture appropriate ensure comparability unless stated otherwise 08 17 absolute term 18 lillys former current wastetolandfill goal include construction demolition debris biosolids wastewater treatment plant incinerator ash coal ash reused mine reclamation road base mycelium urea reused fertilizer 48 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 product stewardship lilly take broad approach understanding lillys approach green chemistry twofold seek managing hse impact across product life ongoing improvement reducing amount scope health safety environment data cycle see page 46 product stewardship standard hazardous material used make product increasing section set expectation address sustainability material efficiency evaluating chemical alternative stage avoiding riskiest substance also pursue data section cover lillys global fundamental changesthat yield orderof operation including whollyowned subsidiary focus following area magnitude improvementsby advancing state unless stated otherwise using green chemistry design environment art chemistry developing implementing new reduce hazardous material use product development following world resource institute guidance reactor technology manufacturing performance data progress toward envi developed several continuous process ronmental goal reported adjusted decreasing environmental impact product basis accounting merger acquisition improve environmental performance enhance manufacturing see performance operation divestiture appropriate ensure process safety reducing operational scale page 51 comparability unless stated otherwise hazardous manufacturing step one reducing environmental impact packaging hundredfold example lilly scientist recently year calendar year unless stated otherwise using sciencebased environmental risk assessment published article green chemistry journal see evaluate potential impact product detail demonstrating new type grignard reaction environment related edivoxetine hydrochloride production innovation reduces process mass intensity disposing product responsibly endoflife 30 percent decrease amount magnesium diisobutylaluminium hydride required innovation green chemistry 99 percent early 1990s lilly one first pharmaceutical lilly also key contributor pharmaceutical company use green chemistry transform roundtable cochairs work group green manufacturing process safer efficient chemistry one focus area 2012 developing environmentally friendly 100000 research grant produce safer solvent also contributed creation public release harmonized solvent selection guide organization capitalizes several company best practice 49 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 packaging pharmaceutical environment product endoflife pharmaceutical packaging highly regulated lilly committed understanding potential effect patient dont finish medication must serve many function including protecting product pharmaceutical residue environment using safely dispose reuse recycling unused medicine integrity transit storage providing information improved testing technology scientist location safe option patient help address issue resisting counterfeiting protecting content around world detected trace amount certain support nationally sanctioned disposal guideline tampering access child sustainable pharmaceutical product stream river reported unused medicine united state also promote packaging effort continually review packaging concentration extremely low ranging public education proper drug disposal example technology practice reduce amount part per trillion part per billion world lilly supporter smarxt disposal consumer packaging used utilize lowerimpact material health organization evaluated selected investigation education program sponsored u fish reuse recycle packaging throughout supply chain conducted australia united kingdom united wildlife service american pharmacist association recent year weve saved thousand metric state case found pharmaceutical pharmaceutical research manufacturer ton packaging million dollar present drinking water concentration generally america phrma see lillys position disposal effort also collaborating distributor less 1000 time minimum therapeutic dos unused medicine united state retail pharmacy healthcare provider better well acceptable daily intake drinking water also support proper disposal syrinx needle understand overall pharmaceutical packaging equivalent level according level suggest sharp used home setting mitigate footprint way reduce significant adverse human health impact highly potential public health environmental risk based unlikely exposure drinking water19 testing feedback patient healthcare provider packaging innovation fegersheim france continues impact persistent ecotoxicity believe education offer greatest opportunity lillys manufacturing site fegersheim france aquatic life optimal path forward address improve sharp disposal practice working replaced disposable cardboard packaging wood issue subject ongoing debate effectively communicate information pallet reusable plastic packaging pallet meet regulatory requirement internal lilly patient product user manual patient education decreased related waste 6 percent equivalent standard assess medicine potential program improved sale force awareness 80 metric ton yearly environmental effect launching new product updated information lilly answer center learn regularly update testing protocol new wwwlillycom existing pharmaceutical knowledge testing method improve continue collaborate regulatory academic research organization advance knowledge area see lillys position pharmaceutical environment 19 world health organization 2012 pharmaceutical drinkingwater isbn 978 92 4 150208 5 available web site wwwwhoint 50 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 performance operation progress toward goalenergy use committed continually improving environmental energy use greenhouse 14000000 700 performance across lillys operation includes gas emission thousand btussquare foot significant area environmental impactenergy 12000000 600 reducing energy use ghg emission improves use ghg emission water use waste environmental performance decrease one 10000000 500 also committed making progress green million btu 2013 substantial operational cost research 8000000 goal 400 procurement reducing nonghg air emission supporting manufacturing distribution activity biodiversity effort community operate 6000000 300 maintaining compliance applicable legal since 2006 conducted 29 energy assessment 4000000 200 standard fundamental part approach energyintensive site uncovered estimated establish work toward share progress 228 million potential annual saving finding 2000000 100 hse performance goal see page 47 contributed approximately 32 million 0 0 cumulative reduction energy spending 20082011 2007 2008 2009 2010 2011 see information commitment helping u avoid nearly 240000 metric ton environmental sustainability direct energy indirect energy energy intensity carbon dioxide equivalent co2e ghg emission consumption consumption time period lilly climate change several facility use renewable energy diversify energy source decrease ghg emission climate change issue compelling cogeneration involves using onsite engine government company citizen act generate electricity well recovering usable heat however believe pose significant another important part approach currently risk opportunity business current anticipated regulatory requirement use two site worldwide another one planned financial implication lilly account routine business planning anticipate impact business strategy 51 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 2011 lillys energy use totaled 10800000 million meet required condition effort enabled progress toward goalghg emission btu 4 percent less 2010 see graph page 51 site reduce electricity use 3 percent gas since 2007 energy intensity per square foot facility use 17 percent 2011 compared 2010 save metric ton co2e1000 square foot space improved 17 percent keeping u track nearly 220000 per year facility also decreased 2000000 90 meet company goal 15 percent improvement co2e emission year 810 metric ton 1750000 80 201320 decrease energy consumed 1500000 70 2013 water use metric ton co2e 2007 2011 equivalent energy used annually goal 60 1250000 approximately 24000 average u home 50 water becoming important issue lilly due 1000000 trend availability quality cost consume 40 2011 company scope 1 scope 2 ghg 750000 emission equaled 1530000 metric ton co2e 4 percent water primarily manufacturing production 30 500000 20 less 2010 see graph right due primarily parenteral operation require exceptionally highquality water produce injectable medicine also use 250000 10 reduced energy usage lillys ghg emission intensity improved 16 percent compared 2007 keeping substantial amount water support utility 0 0 2007 2008 2009 2010 2011 u track meet company goal 15 percent site updated waterless cooling system improvement 201321 others installed technology reclaims water scope 1 scope 2 greenhouse gas purpose lesser extent also consume emission intensity lilly also calculates scope 3 ghg emission included water domestic us office cafeteria summary data table page 56 included bathroom landscaping graph right progress toward goalwater intake 2011 used world business council see lillys recent carbon disclosure project submission sustainable development global water tool additional detail company approach united nation environment programme vital water 20 performance graphic tool refine evaluation waterstressed 18 area operate although determined possible 16 optimizing hvac use alcobendas spain 14 billion liter impact minimal require facility use heating ventilation air conditioning hvac 12 local businesscontinuity plan generated equipment represents 75 percent energy use 10 risk assessment source business interruption alcobendas spain facility save resource 8 including water availability 2011 site optimized system setting enabled 6 equipment enter lowenergy mode fresh air 4 2 0 20 following world resource institute guidance progress toward environmental goal reported adjusted basis accounting merger acquisition divestiture 2007 2008 2009 2010 2011 2013 appropriate ensure comparability unless stated otherwise goal 21 goal cover lillys scope 1 scope 2 emission updated 52 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 manufacturing administration group well 2011 total waste generation increased 6 percent progress toward goalwaste generation lilly research laboratory implemented plan 2010 242000 metric ton see graph right reduce water consumption measure progress largely due increased insulin production target contribute overall water use reduction indianapolis puerto rico plant 450000 25 metric tonsmillion revenue goal assist site identifying watersaving year lilly sent 10900 metric ton waste landfill 400000 technology financing 15900 metric ton 2010 66 percent 350000 20 less 2007 see graph right 300000 2011 lillys water intake22 133 billion liter 4 15 metric ton 250000 percent increase 2010 see graph page 52 reduction total waste generated 2007 200000 primarily due increased production water 2011 equivalent amount waste produced 10 intensity per unit revenue improved 1 percent year 27000 u resident 150000 period 100000 5 50000 decrease water intake 2007 2009 0 0 sale marketing 2007 2008 2009 2010 2011 equivalent water consumed year city approximately 80000 people recently implemented green quest scorecard hazardous nonhazardous waste generation sale marketing site america waste generation waste generation intensity waste canada europe identify score progress toward reducing energy use water consumption lilly us following hierarchy waste treatment transportation year affiliate look progress toward goalwaste landfill eliminate reduce amount waste produced opportunity enhance environmental performance identifying planning new reuse material possible often multiple time project setting target 35000 recycle used material make new product 30000 recover energy waste 25000 treat waste reduce toxicity volume metric ton 20000 send waste landfill option feasible 15000 10000 5000 22 water intake total amount water coming facility including water pumped body surface water groundwater water provided 0 utility includes water used process utility ancillary operation irrigation term include groundwater pumped solely 2007 2008 2009 2010 2011 2013 treatment satisfy regulatory action requirement eg remediation activity water used another purpose value include water goal extracted well solely purpose lowering groundwater table maintain physical structural integrity building foundation water intake updated value 2010 adjusted previously reported value due metering data evaluation one top water use site 53 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 driving process innovation speke example include following united kingdom guayama puerto rico facility maintains speke united kingdom manufacturing facility 10 acre within ground ecological habitat antibiotic production process require substantial conservation area help preserve restore amount water steam natural resource vibrant plant life country space divided last year collaborated three area focus education reforestation external partner develop test enhancement preservation substantially improved efficiency site augusta georgia united state manufacturing process separate solid within waste stream site manages 650acre farm burke county enhancing capability handle highly variable facility wildlife habitat committee focus enhancing feed input innovation decreased water usage biodiversity site implementation 143 million liter per year 10 percent total wildlife management plan usage site reducing steam 7000 metric ton 5 percent overall use facility clinton indiana united state early 2011 change saved 560000 2012 projected introduced project showcase compatibility waste stream reduction related initiative could conservation farming protecting push annual saving 2 million 300 acre manufacturing facility location conservation easement forever protect biodiversity land lilly long history working collaboratively believe lilly operation limited impact protect habitat reduce impact operation biodiversity example commissioned ecosystem pursue decentralized approach longterm study kinsale harbour near manufacturing recognizing biodiversity challenge opportunity site southern ireland study ongoing since 1978 vary based location engage conservation suggested minor change observed project habitat enhancement many site aquatic life kinsale harbour associated natural worldwide also support conservation effort stress storm event rather discharge community facility located effect facility overall harbor ecologic system shown high resilience ability thoroughly handle wastewater discharge 54 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 environmental compliance routine inspection 2006 2007 u environmental award environmental protection agency identified potential recognition lillys policy comply applicable health safety weakness leak detection repair program environment regulation wherever business lilly technology center facility indianapolis indiana believe compliance foundational maintaining addition 2006 voluntarily reported state facility righttooperate local community city environmental agency exceeded see page 47 information hse policy annual limit air emission response event standard management system determined implemented numerous corrective action compliance work remedy enhancement environmental program paid situation quickly possible penalty 337500 early 2011 settle case use environmental capability assessment harm done employee neighbor listed 66th greenest u company 2011 apply statistical processcontrol technique key environment result event environmental compliancerelated process reduce see summary data table page 56 detail number permit exceedance recognition carbonmanagement program united kingdom operation 2011 wildlife work certification 2010 55 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 23 24 fostering environmental sustainability summary data table 2007 2008 2009 2010 2011 energy use energy consumption million btu 12900000 11900000 11300000 11200000 10800000 energy intensity thousand btussquare foot 594 562 543 520 495 energy intensity million btusmillion revenue 692 584 517 485 470 direct energy consumption million btu 4670000 4510000 4230000 4190000 4370000 coal million btu 1410000 1290000 1140000 1280000 1170000 natural gas million btu 2480000 2400000 2400000 2200000 2300000 fuel oil million btu 768000 801000 661000 687000 459000 liquid propane million btu 18600 21500 29600 22700 15900 indirect energy consumption million btu 8240000 7360000 7120000 7000000 6860000 purchased electricity million btu 4630000 4500000 4350000 4310000 4180000 purchased steam million btu 2990000 2610000 2310000 2200000 2240000 purchased chilled water million btu 619000 254000 449000 491000 445000 greenhouse gas emission greenhouse gas emission scope 1 scope 2 metric ton co2e 1810000 1730000 1640000 1600000 1530000 scope 1 502000 483000 468000 452000 410000 scope 2 1310000 1250000 1170000 1150000 1120000 greenhouse gas emission intensity metric ton co2e1000 square foot 833 822 782 745 700 greenhouse gas emission intensity metric ton co2emillion revenue 971 851 752 695 630 scope 3 emission included metric 25 employee business travel personal car taxi rental car rail 65000 65000 63000 72000 67000 air travel metric ton co2e 23 segment add total due rounding employee commuting metric ton co2e 76000 76000 76000 72000 71000 24 energy use greenhouse gas emission except scope 3 wateruse data reported adjusted basis accounting merger acquisition product transportation distribution contracted metric ton co2e 30000 26000 39000 43000 50000 divestiture data table nonadjusted waste generated operation metric ton co2e 15000 14000 11000 17000 20000 25 data include salesforce travel using company vehicle use lilly aircraft product distribution lilly vehicle item nonkyoto compound emission refrigerant vocs etc metric ton co2e 14000 33000 15000 23000 54000 scope 1 included data 56 lilly 20112012 corporate responsibility update fostering environmental sustainability 01 02 03 04 05 06 07 08 09 2007 2008 2009 2010 2011 water use water intake billion liters26 196 176 132 128 133 municipal billion liter 65 66 surface billion liter 0 0 groundwater billion liter 63 68 water intensity million litersmillion revenue 105 0864 0605 0555 0549 waste waste generation metric ton 379000 387000 287000 228000 242000 hazardous waste generation metric ton 53800 55500 46400 31000 22000 nonhazardous waste generation metric ton 325000 331000 241000 197000 220000 waste generation intensity metric tonsmillion revenue 203 190 131 988 107 waste disposition beneficially reused metric ton 253900 198700 201600 148800 176200 recycled includes incineration energy recovery metric ton 31500 102000 28800 45000 35500 treated includes incineration without energy recovery metric ton 49100 49700 35600 12300 13300 26 water intake used evaluating progress toward waterreduction goal total amount water coming facility including water landfilled metric ton 44700 32600 21200 22100 17000 pumped body surface water groundwater water provided utility includes water used process utility ancil landfilled related goal metric tons27 32000 22300 14800 15900 10900 lary operation irrigation term include groundwater pumped solely treatment satisfy regulatory action requirement eg remediation activity water used another purpose air emission value include water extracted well solely purpose volatile organic compound emission metric ton 526 560 549 626 735 lowering groundwater table maintain physical structural integrity building foundation data breakdown water intake source particulate matter metric ton 311 293 384 200 146 available prior 2010 water intake value 2010 adjusted previously reported value due metering data evaluation one top so2 emission metric ton 3137 3188 2589 2015 1160 water use site nox emission metric ton 1205 1322 1125 877 798 27 former current wastetolandfill goal include construction demolition debris biosolids wastewater treatment plant incinera ozonedepleting substance potential kg cfc11 equivalent 795 2376 749 790 3630 tor ash coal ash reused mine reclamation road base mycelium urea reused fertilizer 28 reportable permitlimit exceedance environmental release air environmental compliance water land outside regulatory limit necessarily result reportable permitlimit exceedances28 43 27 16 11 8 harm people environment 29 significant spill report refers unexpected unintended abnor number significant spill 29 0 0 0 0 0 mal unapproved dumping leakage drainage seepage discharge loss substance resulted damage environment ie environmental fine paid 96900 0 12000 1200 34000030 human health aquatic life wildlife material event requiring reporting u security exchange commission damage mean actual imminent alteration environment render environment energy waste natural resource reduction fund harmful detrimental injurious expenditure million 0 65 57 41 08 30 see page 55 detail 57 lilly 20112012 corporate responsibility update lorem ipsum united nation global compact index 01 02 03 04 05 06 07 08 09 united nation global compact index ungc principle location report principle 1 b usinesses support respect protection internationally proclaimed human right managing supply chain page 1011 principle 2 business make sure complicit human right abuse managing supply chain page 1011 principle 3 business uphold freedom association effective recognition right collective bargaining supporting strong workplace practice page 31 principle 4 business uphold elimination form forced compulsory labour managing supply chain page 1011 principle 5 business uphold effective abolition child labour managing supply chain page 1011 principle 6 business uphold elimination discrimination respect employment occupation diversity inclusion page 3435 principle 7 business support precautionary approach environmental challenge fostering environmental sustainability page 4457 principle 8 business undertake initiative promote greater environmental responsibility fostering environmental sustainability page 4457 principle 9 business encourage development diffusion environmentally friendly technology fostering environmental sustainability page 4457 principle 10 business work corruption form including extortion bribery conducting business ethically transparently page 0709 58 lilly 20112012 corporate responsibility update lorem ipsum report 01 02 03 04 05 06 07 08 09 report eli lilly company 20112012 corporate content data report responsibility update report highlight progress externally verified lilly follows structured process initiative since 2010 corporate responsibility collect evaluate calculate data report report also serf lillys annual communication ensure appropriateness accuracy consider progress united nation global compact ungc external standard deciding data collect lilly signatory ungc strategic policy report example following guidance world initiative business committed aligning resource institute report progress toward envi operation strategy 10 universally ronmental goal adjusted basis accounting accepted principle area human right labor merger acquisition divestiture appropriate environment anticorruption index ensure comparability unless stated otherwise ungc indicator report found page 58 global health safety environment management information ungc found system certified independent accredited auditor wwwunglobalcompactorg accordance american chemistry council responsible care management system requirement data update contained report focused 2011 calendar year include global welcome feedback report help u operation unless otherwise noted also discus improve future report please contact data trend previous year relevant include significant event initiative robert smith occurred first half 2012 report senior director corporate responsibility include joint venture partially owned subsidiary president eli lilly company foundation leased facility outsourced operation email phone financial information prepared according robsmithlillycom 3172762000 generally accepted accounting principle gaap united state subject internal accounting control system external thirdparty audit dollar amount given u dollar 59 lilly 20112012 corporate responsibility update wwwlillycom